ClinicalTrials.Veeva

Menu
H

Hillcrest Medical Research, LLC | DeLand, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

sodium
Dapansutrile
Inclisiran
Orforglipron
JATENZO®
STS101
Ezetimibe
LY3502970

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 12 total trials

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men...

Active, not recruiting
Hypogonadism
Drug: Jatenzo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo
Locations recently updated

The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.

Enrolling
Gouty Arthritis
Gout Attack
Other: Placebo Tablet
Drug: Dapansutrile

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Novartis logo
E
F
Lilly logo
L
Merck Sharp & Dohme (MSD) logo
Moderna logo
O
S
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems